Ferric derisomaltose · Monoferric / Monofer

Other

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Kidney Disease, Iron Deficiency Anemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Heart Failure · Phase 3 · investigational in the US

Also approved (2)
JP
  • Treatment of iron-deficiency anemia
Product first approved 2022PMDA
CA
  • Iron deficiency anaemia in adults intolerant of or unresponsive to oral iron
Product first approved 2018Outside this platform's coveragedhpp.hpfb-dgpsa.ca

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (31)
Chronic Kidney Disease
NCT01222884 · Pharmacosmos A/S
2011-06 – 2013-12 · Chronic Kidney Disease Stage 5 (Dialysis Dependent)
What this study did
Heart Failure
Iron Deficiency Anemia
NCT05179226 · Pharmacosmos A/S
2022-11-28 – 2027-04-30 · Iron Deficiency, Anaemia in Children
What this study did
NCT05462704 · Women and Infants Hospital of Rhode Island
2023-01-17 – 2027-03-31 · Iron Deficiency Anemia, Pregnancy
What this study did
NCT03238911 · Pharmacosmos A/S
2017-10-24 – 2018-06-19 · Iron Deficiency Anaemia, Iron Deficiency Anemia
What this study did
NCT02962648 · Pharmacosmos A/S
2017-01-09 – 2018-06-12 · Iron Deficiency Anemia, Iron Deficiency Anaemia
What this study did
NCT03237065 · Pharmacosmos A/S
2017-10-30 – 2018-05-29 · Iron Deficiency Anaemia, Iron Deficiency Anemia
What this study did
NCT02172001 · Pharmacosmos A/S
est. completion 2015-03 · Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT06248749 · University of Saskatchewan
2024-02-29 – 2029-12-01 · Anaemia in Ovarian Carcinoma
What this study did
NCT05407987 · AHS Cancer Control Alberta
2025-04-08 – 2027-12-30 · Gynecologic Cancer, Anemia, Iron-deficiency
What this study did
NCT06884280 · Hull University Teaching Hospitals NHS Trust
2025-11-13 – 2027-10 · Peritoneal Dialysis, Anaemia, Iron Deficiency, Anaemia
What this study did
NCT05251493 · Saskatchewan Health Authority - Regina Area
2022-06-06 – 2026-06-01 · Iron Deficiency Anaemia in Childbirth
What this study did
NCT05768997 · Hallym University Medical Center
2023-03-01 – 2025-12-31 · Anemia
What this study did
NCT05304442 · Baylor College of Medicine
2022-09-15 – 2025-04 · Anemia, Iron Deficiency, Uterine Bleeding
What this study did
NCT05467319 · Alberta Health Services, Calgary
2022-09-30 – 2023-12 · Gynecologic Cancer, Anemia, Iron Deficiency, Surgery
What this study did
NCT02972294 · University Hospital, Angers
2017-03-31 – 2021-09-16 · Hip Fractures Pathologic, Anemia
What this study did
NCT03565354 · Prince of Wales Hospital, Shatin, Hong Kong
2018-07-01 – 2020-06-30 · Anemia, Iron-Deficiency, Colorectal Cancer
What this study did
NCT01895231 · Pharmacosmos A/S
2013-06 – 2016-12 · Iron-deficiency
What this study did
NCT01895205 · Pharmacosmos A/S
2013-06 – 2015-08 · Severe Postpartum Haemorrhage
What this study did
NCT02130063 · Pharmacosmos A/S
2014-05 – 2015-08 · Iron Deficiency Anaemia
What this study did
NCT01895218 · Pharmacosmos A/S
2013-06 – 2014-12 · Postpartum Haemorrhage
What this study did
NCT01599702 · Pharmacosmos A/S
2012-05 – 2014-12 · Inflammatory Bowel Disease
What this study did
NCT01410435 · Pharmacosmos A/S
2011-06 – 2013-09 · Inflammatory Bowel Disease, Anaemia
What this study did
NCT01017614 · Pharmacosmos A/S
2009-10 – 2012-08 · Inflammatory Bowel Disease
What this study did
Phase 2/3 (2)
Heart Failure
NCT04945707 · Massachusetts General Hospital
2021-11-26 – 2026-08-01 · Iron-deficiency, Heart Failure With Preserved Ejection Fraction
What this study did
Other / comorbidity
NCT03662789 · Oslo University Hospital
2018-04-25 – 2020-02-27 · Heart Transplant Recipients
What this study did
Phase 2 (6)
Heart Failure
NCT07643818 · Government of Jersey
2026-06-19 – 2029-12 · Heart Failure With Preserved Ejection Fraction (HFpEF
What this study did
Iron Deficiency Anemia
NCT06287619 · University Health Network, Toronto
2025-04-03 – 2027-06 · Chronic Iron Deficiency Anaemia, Cardiac Surgery
What this study did
NCT05913414 · Sun Yat-sen University
2023-05-05 – 2026-05-30 · Nasopharyngeal Carcinoma, Iron-deficiency, Anemia
What this study did
Other / comorbidity
NCT05220800 · Zealand University Hospital
2022-03-01 – 2029-03-01 · Iron-deficiency, Colorectal Cancer
What this study did
NCT04206228 · Oslo University Hospital
2020-01-13 – 2022-02-15 · Severe Aortic Stenosis, Iron-deficiency
What this study did
NCT02484768 · Pharmacosmos A/S
2015-01 – 2015-02 · Restless Legs Syndrome
What this study did
Phase 1 (9)
Chronic Kidney Disease
NCT01213992 · Pharmacosmos A/S
2012-03 – 2012-11 · Non-dialysis Dependent Chronic Kidney Disease
What this study did
Iron Deficiency Anemia
NCT07790562 · Sichuan Huiyu Pharmaceutical Co., Ltd
2026-07-23 – 2027-01 · Iron Deficiency Anemia
What this study did
Other / comorbidity
NCT05763043 · Oregon Health and Science University
2024-01-18 – 2028-10 · Obstetric Labor Complications
What this study did
NCT04061655 · Ain Shams University
2019-09-20 – 2020-01-10 · Complications
What this study did
NCT03013439 · Pharmacosmos A/S
2017-01-06 – 2017-06-04 · Anemia, Deficiency Diseases, Anemia, Iron Deficiency, Hematologic Disease, Iron Metabolism Disorders
What this study did
NCT01213680 · Pharmacosmos A/S
2012-02 – 2012-11 · Inflammatory Bowel Disease
What this study did
Phase 4 (24)
Chronic Kidney Disease
NCT05719376 · Yonsei University
2023-02 – 2026-06 · Kidney Failure, Chronic
What this study did
Heart Failure
NCT07686692 · Duke University
2026-11 – 2030-08 · Heart Failure With Preserved Ejection Fraction, Iron Deficiency
What this study did
NCT06427343 · China-Japan Friendship Hospital
2023-10-01 – 2027-08-01 · Heart Failure, Iron Deficiency
What this study did
NCT05971732 · China-Japan Friendship Hospital
2023-08-01 – 2027-08-01 · Heart Failure With Reduced Ejection Fraction, Iron Deficiency, Acute Heart Failure
What this study did
NCT05991128 · China-Japan Friendship Hospital
2023-08-01 – 2027-08-01 · Heart Failure With Preserved Ejection Fraction, Iron Deficiencies, Acute Heart Failure
What this study did
NCT02642562 · University of Glasgow
2016-08 – 2022-08-26 · Chronic Heart Failure, Iron Deficiency, Left Ventricular Systolic Dysfunction
What this study did
Iron Deficiency Anemia
NCT07238972 · Yonsei University
2025-12 – 2030-10 · Anemia, Iron Deficiencies, Iron Deficiency Anemia, Cardiac Surgery, Heart Valve Diseases
What this study did
NCT05929729 · Children's Hospital Los Angeles
2023-12-07 – 2028-09-01 · IDA - Iron Deficiency Anemia, Anemia, Iron Deficiency Anemia, Anemia, Iron Deficiency
What this study did
NCT04913649 · dr. P. Noordzij
2021-09-23 – 2026-12 · Iron Deficiency Anemia
What this study did
NCT05358509 · Thomas Jefferson University
2021-03-15 – 2024-01-21 · Iron Deficiency Anemia, Infant, Low Birth Weight, Anemia of Pregnancy
What this study did
NCT03188445 · Pharmacosmos A/S
2017-07-11 – 2020-08-18 · Iron Deficiency Anemia of Pregnancy
What this study did
Other / comorbidity
NCT07659184 · University of Aarhus
2026-10-01 – 2028-09-30 · Hip Fracture, Anemia, Iron, Placebo - Control
What this study did
NCT06898814 · Soren Overgaard
2025-06-09 – 2027-09-14 · Hip Fracture, Anemia
What this study did
NCT05714007 · Peking Union Medical College Hospital
2023-08-31 – 2025-12 · Perioperative Anemia, Surgery, Spinal Deformity, Adult
What this study did
NCT05258825 · Brigham and Women's Hospital
2023-04-18 – 2025-06-25 · Anemia, Surgery
What this study did
NCT04608539 · Michael Kremke
2021-05-21 – 2023-06-27 · Anemia Postoperative
What this study did
NCT04346004 · Yonsei University
2020-04-27 – 2023-03 · Aortic Stenosis (Treated With TAVI)
What this study did
NCT04505514 · University of Malaya
2020-08-01 – 2022-12-31 · Post Partum Hemorrhage, Anemia
What this study did
NCT02905539 · Universität des Saarlandes
2016-07 – 2020-06 · Anemia, Iron-Deficiency
What this study did
NCT03229954 · Yonsei University
2017-08-28 – 2019-04 · Post Gastrectomy Anemia
What this study did
NCT02999217 · Kaunas University of Medicine
2016-10 – 2018-10 · Anemia, Iron-Deficiency, Intravenous Drug Usage, Colorectal Neoplasms, Colorectal Surgery
What this study did
NCT01927328 · Nottingham University Hospitals NHS Trust
2013-08 – 2017-08 · Anemia, Esophageal Cancer, Gastric Cancer
What this study did
Early phase / not applicable (10)
Iron Deficiency Anemia
NCT03610230 · The University of Hong Kong
2019-02-01 – 2021-03-30 · Iron Deficiency Anemia Treatment
What this study did
Other / comorbidity
NCT07236788 · China-Japan Friendship Hospital
2025-03-01 – 2027-03-30 · Obesity, Anemia, Iron Deficiencies, Bariatric Surgery
What this study did
NCT05581420 · Leiden University Medical Center
2022-06-02 – 2025-05 · Inflammatory Bowel Diseases
What this study did
NCT05221957 · Zealand University Hospital
2022-03-01 – 2023-12 · Colorectal Cancer, Anemia, Iron-deficiency
What this study did
NCT03888768 · Ministry of Health, Malaysia
2019-08-01 – 2021-12 · Iron-deficiency
What this study did
NCT02862665 · Yonsei University
2016-08 – 2020-05-07 · Complex Valvular Heart Surgery
What this study did
NCT03094182 · Yonsei University
2017-03-02 – 2019-08 · Facial Asymmetry, Retrognathism, Prognathism
What this study did
NCT03470649 · Seoul National University Hospital
2018-03-29 – 2019-04-17 · Anemia, Knee Arthropathy
What this study did
NCT01628770 · Dow University of Health Sciences
2012-05 – 2012-12 · Postpartum Anemia
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Heart Failure: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ferric Derisomaltose (Monoferric / Monofer): this drugPhase 3Iron Complex (iv)Iron repletionWeak signal
NCT00537186: Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks.
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT04564742: Primary hierarchical composite outcome (win ratio analysis, DAPA-MI): win ratio 1.34 (95% CI 1.20-1.50), P<0.001, favoring dapagliflozin over placebo; n=4017 (2019 dapagliflozin vs 1998 placebo)
NCT03619213: Primary composite outcome (worsening heart failure or cardiovascular death): dapagliflozin 16.4% vs placebo 19.5%; hazard ratio 0.82 (95% CI 0.73-0.92, p<0.001)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03057951: Primary composite endpoint (CV death or HF hospitalization) event rate: 13.8% (empagliflozin) vs 17.1% (placebo); HR 0.79, 95% CI 0.69-0.90; 21% relative risk reduction.
NCT03057977: Primary composite outcome (cardiovascular death or hospitalization for worsening heart failure) at median 16 months: 19.4% (361/1863) with empagliflozin vs 24.7% (462/1867) with placebo; hazard ratio 0.75 (95% CI 0.65-0.86), P<0.001
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT03037931: Primary endpoint, hierarchical composite of death and heart failure hospitalization at 12 months and change in 6-minute walk distance at 6 months (significance level 0.01): unmatched win ratio 1.10 (99% CI 0.99 to 1.23), Wilcoxon-Mann-Whitney P=0.02. Components, ferric carboxymaltose vs placebo: deaths 131 (8.6%) vs 158 (10.3%); heart failure hospitalizations 297 vs 332; 6-minute walk change +8 vs +4 m. missed
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT04435626: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Finerenone (BAY94-8862) 1083 events | Placebo 1283 events
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2Weak signalFeatured results are non-efficacy only in this race
Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Isosorbide Dinitrate / Hydralazine (BiDil)ApprovedSmall moleculeHydralazine/isosorbide dinitrate (fixed combination)Partial signal
NCT00047775: Primary composite score (all-cause mortality, first heart-failure hospitalization, quality of life) favoured isosorbide dinitrate/hydralazine vs placebo (p=0.021); the trial stopped early for a 43% reduction in all-cause mortality (p=0.012) (BiDil label, A-HeFT).
Ivabradine (Corlanor)
ApprovedUS marketing discontinued
Small moleculeIf (funny) channelReliable signal
NCT02441218: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. (All over the study (up to 42 months).): Ivabradine 793 participants | Placebo 937 participants
Sacubitril / Valsartan (Entresto)ApprovedSmall moleculeNeprilysin + Angiotensin II receptor (dual)Partial signal
NCT01035255: Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization (up to 51 months): LCZ696 — Primary Composite: 914 participants; CV death: 558 participants; 1st HF Hospitalization: 537 participants | Enalapril — Primary Composite: 1117 participants; CV death: 693 participants; 1st HF Hospitalization: 658 participants
NCT01920711: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. (Total follow up time (up to 57 months)): LCZ696 — Primary Composite Events: 894 Events; Total Hospitalizations for heart failure: 690 Events; Cardiovascular death: 204 Events | Valsartan — Primary Composite Events: 1009 Events; Total Hospitalizations for heart failure: 797 Events; Cardiovascular death: 212 Events missed
Sotagliflozin (Inpefa)ApprovedSmall moleculeSGLT1/2 (dual)Partial signal
NCT03315143: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 30 months): Sotagliflozin 5.6 events per 100-person years | Placebo 7.5 events per 100-person years
NCT03521934: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 21.9 months): Sotagliflozin 51 events per 100-person years | Placebo 76.3 events per 100-person years
Torsemide (Soaanz)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Vericiguat (Verquvo)ApprovedSmall moleculeSoluble guanylate cyclasePartial signal
NCT02861534: CV death or first HF hospitalization, vericiguat vs placebo: 897 of 2526 (35.5%) vs 972 of 2524 (38.5%) over a median 10.8 months; HR 0.90 (95% CI 0.82 to 0.98), P = 0.02. Met.
NCT05093933: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years (Up to approximately 36 months (from randomization to the primary completion data cutoff)): Vericiguat 11.3 Pts. with event/100 patient-yrs at risk | Placebo 12.2 Pts. with event/100 patient-yrs at risk missed
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet gradedNo reviewed efficacy summary in this indication
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
CardiAMPPhase 3Cell therapyCardiac cell therapyPartial signal
NCT02438306: 3-tiered Finkelstein-Schoenfeld primary endpoint at 12 months (interim, 102 of eventual 125 patients): Tier 1 all-cause death 5.6% CardiAMP vs 5.3% control (P=.42); Tier 2 MACCE 16.7% vs 15.8% (P=.82); Tier 3 6MWT change +36.1m vs +33.4m (P=.6) - none reached significance; DSMB futility review concluded the trial was unlikely to meet its primary endpoint missed
CoramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HiCM-188 (allogeneic iPSC-Cardiomyocytes)Phase 3Cell therapyCardiac cell therapyPartial signalNo reviewed efficacy summary in this indication
Icodextrin (peritoneal Ultrafiltration) (Extraneal)Phase 3Glucose Polymer Solution (peritoneal Dialysis)Peritoneal ultrafiltrationWeak signal
NCT00368641: All-cause Hospitalization (Unadjusted) (6 to 24 months): Intervention Group 5.33 hospitalizations per year (95% CI 3.13 to 9.05) vs Standard Therapy 1.69 hospitalizations per year (95% CI 0.95 to 2.99)
Levosimendan (Simdax)Phase 3Small moleculeCardiac troponin C (calcium sensitizer)Partial signal
NCT00348504: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P = .40). missed
NCT00048425: REVIVE II, n=600: 5-day clinical-course composite primary endpoint improved 33% more often and worsened 26% less often with levosimendan vs placebo (p=0.015).
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
Omecamtiv MecarbilPhase 3Small moleculeCardiac myosin (activator)Reliable signal
NCT02929329: Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Omecamtiv Mecarbil 37% vs Placebo 39.1%
NCT03759392: Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 (Baseline and Week 20): Omecamtiv Mecarbil -0.239 mL/min/kg (Standard Error 0.1718) vs Placebo 0.207 mL/min/kg (Standard Error 0.2412) missed
OPC-61815 (Samtasu)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT03772041: Change From Baseline in Body Weight (Baseline, Day 6): OPC-61815 Injection 16 mg -1.67 kg (95% CI -1.93 to -1.41) vs Tolvaptan Tablet 15mg -1.36 kg (95% CI -1.62 to -1.1)
QiShenYiQiPhase 3BotanicalTraditional Chinese medicine (multi-component)Partial signalNo reviewed efficacy summary in this indication
Recombinant Human Neuregulin-1 (rhNRG-1) (Neucardin)Phase 3Protein / enzyme therapeuticErbB2/ErbB4 (neuregulin pathway)Partial signalNo reviewed efficacy summary in this indication
Rexlemestrocel-LPhase 3Cell therapyMesenchymal precursor cells (MPCs)Weak signalFeatured results are safety only in this race
Sotatercept (Winrevair)Phase 3Protein / enzyme therapeuticActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Samsca)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT00071331: All-cause mortality: tolvaptan 25.9% vs placebo 26.3% (HR 0.98, 95% CI 0.87-1.11, P=.68). Composite of CV death or HF hospitalization: tolvaptan 42.0% vs placebo 40.2% (HR 1.04, 95% CI 0.95-1.14, P=.55). missed
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
DanicamtivPhase 2/3Small moleculeCardiac myosin (activator)Weak signal
NCT03447990: Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts.
IstaroximePhase 2/3Small moleculeNa-K ATPase / SERCA2aPartial signal
NCT02617446: Change in E/Ea Ratio (24 hours): Istaroxime 0.5 µg/kg/Min -4.55 Unitless ratio (95% CI -6.05--3.04) vs Placebo Cohort I -1.55 Unitless ratio (95% CI -3.77-0.67) vs Istaroxime 1.0 µg/kg/Min -3.16 Unitless ratio (95% CI -4.09--2.24) vs Placebo Cohort II -1.08 Unitless ratio (95% CI -2.30-0.13); p=0.029 (Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I), p=0.009 (Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II)
AC01Phase 2Small moleculeGhrelin receptorWeak signalNo reviewed efficacy summary in this indication
ADR-002KPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
Bucindolol (Gencaro)Phase 2Small moleculeBeta-1/beta-2 adrenergic receptor (genotype-guided)Partial signal
NCT01970501: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24]. (end of treatment week 24): Bucindolol Hydrochloride 35.9 days (IQR 9 to 53) vs Metoprolol Succinate 33.2 days (IQR 6 to 47) missed
CDR132LPhase 2RNA / oligonucleotidemicroRNA-132Weak signalFeatured results are safety only in this race
Corteria COR-1167Phase 2PeptideCorticotropin-releasing factor receptor 2not yet gradedNo reviewed efficacy summary in this indication
DelocamtenPhase 2Small moleculeCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
DeramiocelPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HRS-9057Phase 2Small moleculeVasopressin V1a/V2 receptor (dual)Weak signalNo reviewed efficacy summary in this indication
HU6Phase 2Small moleculeMitochondrial uncouplingPartial signal
NCT05284617: Weight change at 3 months (450 mg HU6 dose): -6.8 lb from baseline (p<0.0001); -6.3 lb vs placebo (p=0.003)
Jia Shen TabletPhase 2BotanicalMulti-target (ginsenoside)Weak signalNo reviewed efficacy summary in this indication
JK07Phase 2Biologic (subtype unspecified)HER3 × ErbB4Weak signalFeatured results are safety only in this race
JTT-861Phase 2Small moleculePyruvate dehydrogenasePartial signalNo reviewed efficacy summary in this indication
Mavacamten (Camzyos)Phase 2Small moleculeCardiac myosin (inhibitor)Weak signalFeatured results are safety only in this race
Ninerafaxstat (IMB-101)Phase 2Small moleculeCardiac fatty-acid oxidationWeak signal
NCT04826159: Primary, resting cardiac PCr/ATP change from baseline (single arm, no comparator): Part 1 (type 2 diabetes and obesity) +0.39 (95% CI 0.16 to 0.62; P=0.002); Part 2 (with HFpEF) +0.15 (95% CI 0.03 to 0.26; P=0.02). Dobutamine-stress PCr/ATP (Part 1) is not reported in the abstract.
PexerelgonPhase 2Small moleculeRelaxin receptor (RXFP1) / relaxinPartial signalNo reviewed efficacy summary in this indication
PF-07328948Phase 2Small moleculeBranched-chain ketoacid dehydrogenase kinase (BDK)not yet gradedNo reviewed efficacy summary in this indication
R2R01Phase 2PeptideRelaxin receptor (RXFP1) / relaxinWeak signalNo reviewed efficacy summary in this indication
RibupatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Safiglipron (HRS-7535)Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
TovinontrinePhase 2Small moleculePDE9Partial signalNo reviewed efficacy summary in this indication
Umiposgene Parvec (AB-1002)Phase 2Gene therapy / editingProtein inhibitor-1 (gene therapy)Weak signal
NCT04179643: Phase 1 first-in-human trial of a single antegrade coronary infusion of AB-1002 in NYHA III non-ischemic heart failure: no adverse events or serious adverse events were attributed by the investigators to the study treatment. Mean left ventricular ejection fraction rose from 30.5% at baseline to 42.2% at 12 months in cohort 1 and from 24.5% to 36.7% in cohort 2, and all patients with baseline and 12-month assessments had an improvement in ejection fraction of at least 5%.
XTR003Phase 2Diagnostic (pet Tracer)Myocardial fatty-acid metabolism (PET imaging)not yet gradedNo reviewed efficacy summary in this indication
AAV1.SERCA2aPhase 1/2Gene therapy / editingSERCA2a (gene therapy)not yet gradedNo reviewed efficacy summary in this indication
HS-001Phase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
HucMSC Intramyocardial TherapyPhase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
PolyCorePhase 1/2SolutionPeritoneal ultrafiltrationnot yet gradedNo reviewed efficacy summary in this indication
Anhui HygeianCells EE001Phase 1Biologic (subtype unspecified)Cardiac cell therapyWeak signalNo reviewed efficacy summary in this indication
HJB647Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 13 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(20 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Monoferric / Monofer (Ferric derisomaltose) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Phase 4Iron Deficiency AnemiaRecruiting
Est. primary completion 2026-11 · NCT04913649 · CT.gov ↗
What to watch
December 2026 (2)
Phase 2Iron Deficiency AnemiaRecruiting
Est. primary completion 2026-12 · NCT06287619 · CT.gov ↗
What to watch
Early phase / not applicableObesity, Anemia, Iron Deficiencies, Bariatric SurgeryRecruiting
Est. primary completion 2026-12-30 · NCT07236788 · CT.gov ↗
What to watch
2027 (10)
March 2027 (1)
Phase 3Iron Deficiency AnemiaRecruiting
Est. primary completion 2027-03-30 · NCT05462704 · CT.gov ↗
What to watch
April 2027 (1)
Phase 3Iron Deficiency AnemiaRecruiting
Est. primary completion 2027-04-30 · NCT05179226 · CT.gov ↗
What to watch
June 2027 (1)
Phase 4Hip Fracture, AnemiaRecruiting
Est. primary completion 2027-06-01 · NCT06898814 · CT.gov ↗
What to watch
August 2027 (3)
Phase 4Heart FailureRecruiting
Est. primary completion 2027-08-01 · NCT06427343 · CT.gov ↗
What to watch
Phase 4Heart FailureRecruiting
Est. primary completion 2027-08-01 · NCT05971732 · CT.gov ↗
What to watch
Phase 4Heart FailureRecruiting
Est. primary completion 2027-08-01 · NCT05991128 · CT.gov ↗
What to watch
October 2027 (2)
Phase 3Peritoneal Dialysis, Anaemia, Iron Deficiency, AnaemiaRecruiting
Est. primary completion 2027-10 · NCT06884280 · CT.gov ↗
What to watch
Phase 4AnemiaNot yet recruiting
Est. primary completion 2027-10-01 · NCT07314424 · CT.gov ↗
What to watch
December 2027 (2)
Phase 3Heart FailureRecruiting
Est. primary completion 2027-12-01 · NCT06929806 · CT.gov ↗
What to watch
Phase 3Gynecologic Cancer, Anemia, Iron-deficiencyRecruiting
Est. primary completion 2027-12-30 · NCT05407987 · CT.gov ↗
What to watch
2028 (4)
September 2028 (2)
Phase 4Iron Deficiency AnemiaRecruiting
Est. primary completion 2028-09-01 · NCT05929729 · CT.gov ↗
What to watch
Phase 4Hip Fracture, Anemia, Iron, Placebo - ControlNot yet recruiting
Est. primary completion 2028-09-30 · NCT07659184 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1Obstetric Labor ComplicationsRecruiting
Est. primary completion 2028-10 · NCT05763043 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Anaemia in Ovarian CarcinomaNot yet recruiting
Est. primary completion 2028-12-01 · NCT06248749 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Phase 2Heart FailureEnrolling by invitation
Est. primary completion 2029-07 · NCT07643818 · CT.gov ↗
What to watch
2030 (2)
August 2030 (2)
Phase 4Iron Deficiency AnemiaNot yet recruiting
Est. primary completion 2030-08 · NCT07238972 · CT.gov ↗
What to watch
Phase 4Heart FailureNot yet recruiting
Est. primary completion 2030-08 · NCT07686692 · CT.gov ↗
What to watch

See the full readout calendar ↗